Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025) [0.03%]
中国临床肿瘤学会乳腺癌专家共识——乳腺癌脑转移诊断和治疗（2025）
Tao Wang,Jiayi Chen,Jin Yang et al.
Tao Wang et al.
Background: Globally, breast cancer (BC) ranks among the most frequently diagnosed malignant tumors in women. Given the high prevalence of BC, brain metastasis (BM) arising from this malignancy are the second most frequen...
Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association [0.03%]
早期乳腺癌患者预后和随访临床实践指南（中国抗癌协会乳房专业委员会，2026版）
Jia Wang,Dianlong Zhang,Yuting Zhang et al.
Jia Wang et al.
Background: Long-term survival in early-stage breast cancer patients has markedly improved, making follow-up an increasingly prolonged phase of care. Accurate prognosis assessment and a scientifically grounded follow-up p...
BRCA and CDK4/6: allies or antagonists?-efficacy of CDK4/6 inhibitors in HR+/HER2- breast cancer with germline BRCA1/2 mutations: a narrative review [0.03%]
BRCA和CDK4/6：盟友还是对手？--BRCA1/2基因 germline突变的HR+/HER2-乳腺癌中使用CDK4/6抑制剂的有效性：综述式文章
Maria Florencia Illia,Giuliana Colucci,Andres Rodriguez Mignola et al.
Maria Florencia Illia et al.
Background and objective: Breast cancer (BC) remains the most prevalent malignancy in women globally, with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors representing appr...
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition) [0.03%]
中国乳腺癌内分泌治疗专家共识(2026版)
Yang Yuan,Yongmei Yin,Shu Wang et al.
Yang Yuan et al.
Background: Endocrine therapy (ET) is the primary treatment for hormone receptor (HR)-positive breast cancer. Based on the 2023 expert consensus, the Chinese Consensus Group on Breast Cancer Endocrine Therapy updated this...
Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer: insights from a large cohort in central south China [0.03%]
中国中部南部地区一大型队列中HR+/HER2-早期乳腺癌患者辅助使用CDK4/6抑制剂的适用性分析
Jianmin Wu,Ziru Zhao,Mengxi Li et al.
Jianmin Wu et al.
Background: The MonarchE and NATALEE trials have established adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) as pivotal therapies for high-risk hormone receptor-positive (HR+) early breast cancer (EBC). However, r...
The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells [0.03%]
PSEN1对乳腺癌细胞增殖和侵袭影响的初步研究
Miao Yang,Jia-Qun Zou,Wei Yang
Miao Yang
Background: Breast cancer is the most common form of cancer among women, and PSEN1 dysfunction is a primary contributor to the pathogenesis of Alzheimer's disease. However, the involvement of PSEN1 in breast cancer remain...
Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review [0.03%]
cyclin依赖性激酶4和6抑制剂在转移性雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌原发性和继发性耐药的生物标志物：叙述性综述
Athina Stravodimou,Ioannis A Voutsadakis
Athina Stravodimou
Background and objective: Cyclin dependent kinases 4 and 6 (CDK4/6) inhibitors are a class of drugs that are used in the first-line therapy of metastatic estrogen receptor (ER) positive/human epidermal growth factor recep...
Prognostic value of RecurIndex in differentiating HER2-low from HER2-negative early-stage breast cancer: a comprehensive clinicopathologic and molecular analysis in Chinese patients [0.03%]
基于中国乳腺癌患者的大样本临床病理及分子研究揭示RecurIndex在HER2低表达早期乳腺癌中的预后价值及其与HER2阴性乳腺癌的差异性
Shuo Zhang,Tianli Hui,Wei Gao et al.
Shuo Zhang et al.
Background: Breast cancer (BC) has become the most prevalent malignancy worldwide in recent years. Human epidermal growth factor receptor 2 (HER2) low-expressing tumors account for approximately 60% of BCs in clinical pra...
Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China [0.03%]
中国洞庭湖地区HR+/HER2-转移性乳腺癌 Cyclin依赖性激酶4/6抑制剂的疗效及预后因素：一项多中心回顾性研究
Binliang Liu,Tao Wu,Kaili Lu et al.
Binliang Liu et al.
Background: CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become the standard of care for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast c...
Social inequalities in survival among women with breast cancer in southeastern Brazil: a retrospective cohort study [0.03%]
巴西东南部乳腺癌女性患者中的生存率差异：一项回顾性队列研究
Raphael Manhães Pessanha,Wesley Rocha Grippa,Luiz Cláudio Barreto Silva Neto et al.
Raphael Manhães Pessanha et al.
Background: Breast cancer (BC) remains the most common malignancy among women worldwide and a leading cause of cancer-related death, particularly in low- and middle-income countries. Social inequalities are known to influ...